JP2012522030A - ヘスペレチンの生体利用率を増大させるためのフラボノイドの使用 - Google Patents
ヘスペレチンの生体利用率を増大させるためのフラボノイドの使用 Download PDFInfo
- Publication number
- JP2012522030A JP2012522030A JP2012502640A JP2012502640A JP2012522030A JP 2012522030 A JP2012522030 A JP 2012522030A JP 2012502640 A JP2012502640 A JP 2012502640A JP 2012502640 A JP2012502640 A JP 2012502640A JP 2012522030 A JP2012522030 A JP 2012522030A
- Authority
- JP
- Japan
- Prior art keywords
- hesperetin
- use according
- compound
- flavonoid compound
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N O=C1c2ccccc2OC(c2ccccc2)=C1 Chemical compound O=C1c2ccccc2OC(c2ccccc2)=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Fodder In General (AREA)
- Saccharide Compounds (AREA)
Abstract
【選択図】なし
Description
(式中、炭素3、5、6、7、8、2’、3’、4’、5’及び/又は6’は、H、OH又はOCH3基で、互いに等しく又は異なるように置換されている)の群から選択することができ、但し、該フラボノイド化合物はヘスペレチンではない。
少なくとも1種のフラボノイド化合物、但し前記フラボノイド化合物はヘスペレチンではない、及び
ヘスペレチン
を含み、少なくとも1種のフラボノイド化合物及びヘスペレチンが、1日用量あたり10ng〜10000mgの量で各々存在する、
組成物である。
(式中、炭素3、5、6、7、8、2’、3’、4’、5’及び/又は6’は、H、OH又はOCH3基で、互いに等しく又は異なるように置換されている)でもよく、但し前記化合物はヘスペレチンではない。
Claims (15)
- 哺乳動物においてヘスペレチン((S/R)−2,3−ジヒドロ−5,7−ジヒドロキシ−2−(3−ヒドロキシ−4−メトキシフェニル)−4H−1−ベンゾピラン−4−オン)の生体利用率を増大させる製品を調製するための、少なくとも1種のフラボノイド化合物、但し前記フラボノイド化合物はヘスペレチンではない、を含む組成物の使用。
- 少なくとも1種のフラボノイド化合物が、ケルセチン、フィセチン、クリシン、アカセチン、アピゲニン、ルテオリン、タンゲリチン、バイカレイン、スクテラレイン、オウゴニン、ジオスミン、及びフラボキサート、ケンフェロール、ミリセチン、フィセチン、イソラムネチン、パキポドール、ラムナジン、ヘスペリジン、ルチン、ガランギン、ケンフェリド、ゲニステイン、ダイゼイン、ビオカニンA、カテキン、エピカテキン、EGCG、フロレチン、並びにこれらの組合せからなる群から選択される、請求項1又は2に記載の使用。
- 前記化合物が、食用フラボノイドの群から選択される、請求項1〜3のいずれか一項に記載の使用。
- 少なくとも1種のフラボノイド化合物が、1日用量あたり0.01mg〜10000mgの量で前記製品中に存在する、請求項1〜4のいずれか一項に記載の使用。
- ヘスペレチンの健康特性を向上させるための、請求項1〜5のいずれか一項に記載の使用。
- 前記組成物が、1日用量あたり、好ましくは0.1mg〜10000mg、より好ましくは1mg〜1000mg、さらにより好ましくは10mg〜500mgの量でヘスペレチンをさらに含み、並びに/或いは、ヘスペレチンが、ミントなどの薬草から、又は柑橘系果実、特にオレンジ、マンダリンミカン、レモン、ライム、及び/若しくはグレープフルーツからの抽出物の形で供給される、請求項1〜6のいずれか一項に記載の使用。
- 生体の抗酸化防御を増大させるための、請求項1〜7のいずれか一項に記載の使用。
- 炎症を治療又は予防するための、請求項1〜7のいずれか一項に記載の使用。
- 生体を毒素から防御するための、請求項1〜7のいずれか一項に記載の使用。
- 静脈瘤、痔核、又は静脈性潰瘍の形成を治療又は予防するための、請求項1〜7のいずれか一項に記載の使用。
- 血中の高コレステロールレベルを治療又は予防するため、HDLコレステロールレベルを増大させるため、及び/又は、トリグリセリドのレベルを低下させるための、請求項1〜7のいずれか一項に記載の使用。
- ウイルス感染症、特に単純ヘルペスI型及び/又はインフルエンザ感染症を治療又は予防するための、請求項1〜7のいずれか一項に記載の使用。
- 癌増殖を治療、予防、又は低減するための、請求項1〜7のいずれか一項に記載の使用。
- 少なくとも1種のフラボノイド化合物、但し前記フラボノイド化合物はヘスペレチンではない、及びヘスペレチンを含み、少なくとも1種のフラボノイド化合物及びヘスペレチンが、1日用量あたり10ng〜10000mgの量で各々存在する、組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09156910.3 | 2009-03-31 | ||
EP09156910A EP2241313A1 (en) | 2009-03-31 | 2009-03-31 | Use of flavonoids to increase the bioavailability of hesperetin |
PCT/EP2010/054215 WO2010112510A1 (en) | 2009-03-31 | 2010-03-30 | Use of flavonoids to increase the bioavailability of hesperetin |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012522030A true JP2012522030A (ja) | 2012-09-20 |
JP2012522030A5 JP2012522030A5 (ja) | 2013-05-09 |
Family
ID=40908614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012502640A Pending JP2012522030A (ja) | 2009-03-31 | 2010-03-30 | ヘスペレチンの生体利用率を増大させるためのフラボノイドの使用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US8685935B2 (ja) |
EP (2) | EP2241313A1 (ja) |
JP (1) | JP2012522030A (ja) |
CN (1) | CN102448455A (ja) |
AR (1) | AR076040A1 (ja) |
AU (1) | AU2010230211A1 (ja) |
BR (1) | BRPI1014083A2 (ja) |
CL (1) | CL2011002451A1 (ja) |
MX (1) | MX2011010376A (ja) |
SG (1) | SG174609A1 (ja) |
WO (1) | WO2010112510A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016216440A (ja) * | 2015-05-14 | 2016-12-22 | 花王株式会社 | カテキン類吸収促進剤 |
JP2019515022A (ja) * | 2016-05-16 | 2019-06-06 | グローバル バイオライフ インコーポレーテッドGlobal Biolife Inc. | 炎症関連疾患及び障害を治療するための求電子的に強化されたフェノール化合物 |
JP2019151568A (ja) * | 2018-03-01 | 2019-09-12 | アサヒ飲料株式会社 | 酸性スフィンゴミエリナーゼ活性向上剤、酸性スフィンゴミエリナーゼ活性向上用組成物、及び抗アレルギー用組成物 |
WO2020153710A3 (ko) * | 2019-01-22 | 2020-10-15 | 조선대학교 산학협력단 | 헤스페레틴을 포함하는 피부과민반응을 조절하기 위한 조성물 |
KR20230095911A (ko) * | 2021-11-16 | 2023-06-29 | 가부시키가이샤 다이토 기켄 | 커피머신 |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100234310A1 (en) * | 2009-03-11 | 2010-09-16 | Bionovo, Inc. | Estrogenic compounds and their methods of use |
CN103462957A (zh) * | 2012-06-07 | 2013-12-25 | 上海中医药大学 | 一种异鼠李素的新用途 |
CN102697768A (zh) * | 2012-06-07 | 2012-10-03 | 中国人民解放军第二军医大学 | 一类木犀草素类似黄酮类化合物在制备抗肿瘤药物中的用途 |
US9053152B2 (en) | 2012-08-06 | 2015-06-09 | Sap Portals Israel Ltd | Search and context based creation in dynamic workspaces |
CN102861090A (zh) * | 2012-10-27 | 2013-01-09 | 吴俊华 | Houttuynoid C在治疗胆管癌药物中的应用 |
CN102861050A (zh) * | 2012-10-27 | 2013-01-09 | 吴俊华 | Houttuynoid A在治疗胰腺癌药物中的应用 |
CN102861053B (zh) * | 2012-10-27 | 2013-07-10 | 南京大学 | Houttuynoid D在治疗白血病药物中的应用 |
CN102861075A (zh) * | 2012-10-27 | 2013-01-09 | 吴俊华 | Houttuynoid B在治疗胃癌药物中的应用 |
CN102861081A (zh) * | 2012-10-27 | 2013-01-09 | 吴俊华 | Houttuynoid C在治疗皮肤癌药物中的应用 |
CN102861046A (zh) * | 2012-10-27 | 2013-01-09 | 南京大学 | Houttuynoid A在治疗卵巢癌药物中的应用 |
CN102861092A (zh) * | 2012-10-27 | 2013-01-09 | 吴俊华 | Houttuynoid C在治疗肺癌药物中的应用 |
CN102861086A (zh) * | 2012-10-27 | 2013-01-09 | 吴俊华 | Houttuynoid E在治疗卵巢癌药物中的应用 |
CN102861048A (zh) * | 2012-10-27 | 2013-01-09 | 吴俊华 | Houttuynoid A在治疗鼻咽癌药物中的应用 |
CN102861060A (zh) * | 2012-10-27 | 2013-01-09 | 吴俊华 | Houttuynoid B在治疗白血病药物中的应用 |
EP2925160B1 (en) * | 2012-11-29 | 2018-03-14 | Nestec S.A. | Increasing the bioavailability of flavan-3-ols by polyphenols |
GB201407694D0 (en) * | 2014-05-01 | 2014-06-18 | Univ Montfort | Compound |
AU2016217912A1 (en) * | 2015-02-11 | 2017-09-28 | Bioactor Bv | Compounds and compositions for improving power output and oxygen efficiency |
US10383842B2 (en) * | 2015-02-13 | 2019-08-20 | Global Biolife Inc. | Method and composition for preventing and treating viral infections |
US20210299088A1 (en) * | 2015-02-13 | 2021-09-30 | Global Biolife Inc. | Method and composition for preventing and treating viral infections |
CN105167193B (zh) * | 2015-06-17 | 2019-02-19 | 湖北中烟工业有限责任公司 | 含黄酮香精的烟用嘴棒及其制备方法 |
CN104983728B (zh) * | 2015-08-07 | 2018-01-05 | 上海中医药大学 | 金合欢素在制备防治溃疡性结肠炎的药物或食品中的应用 |
KR101725461B1 (ko) * | 2015-12-29 | 2017-04-10 | 연세대학교 산학협력단 | 디오스민을 유효성분으로 포함하는 탈모 예방 또는 치료용, 또는 발모 또는 육모 촉진용 조성물 |
AU2017429594B2 (en) * | 2017-08-28 | 2024-05-30 | Global Biolife Inc. | Method and composition for preventing and treating viral infections |
KR20210021827A (ko) | 2019-08-19 | 2021-03-02 | 연세대학교 산학협력단 | 켐페라이드를 유효성분으로 포함하는 대사질환의 예방 또는 치료용 조성물 |
CN111281866B (zh) * | 2020-03-30 | 2021-09-28 | 中国药科大学 | 一种预防或治疗溃疡性结肠炎的中药化学制剂 |
CN112569246A (zh) * | 2020-12-22 | 2021-03-30 | 成都大学 | 用于抗炎镇痛止血的药物及药物活性组分筛选方法 |
CN114948977B (zh) * | 2021-02-25 | 2023-11-28 | 南京中医药大学 | 二氢黄酮苷衍生物在制备防治结肠炎的药物中的用途 |
CN113679733A (zh) * | 2021-08-31 | 2021-11-23 | 广东金骏康生物技术有限公司 | 一种抑制结肠炎的化合物及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003073279A (ja) * | 2001-08-31 | 2003-03-12 | Toyo Seito Kk | 即効性および持続性を有するフラボノイド配糖体を含有する経口栄養補給剤 |
US20030144219A1 (en) * | 2001-11-15 | 2003-07-31 | Phinney Stephen Dodge | Formulations and methods for treatment or amelioration of inflammatory conditions |
JP2009209066A (ja) * | 2008-03-03 | 2009-09-17 | Toyo Seito Kk | 生体吸収性に優れたヘスペレチン組成物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0695181A1 (en) | 1993-04-20 | 1996-02-07 | The Procter & Gamble Company | Methods of using hesperetin for sebum control and treatment of acne |
JPH08283154A (ja) * | 1995-04-12 | 1996-10-29 | Nippon Shinyaku Co Ltd | 脂質代謝改善剤 |
-
2009
- 2009-03-31 EP EP09156910A patent/EP2241313A1/en not_active Withdrawn
-
2010
- 2010-03-30 BR BRPI1014083A patent/BRPI1014083A2/pt not_active IP Right Cessation
- 2010-03-30 JP JP2012502640A patent/JP2012522030A/ja active Pending
- 2010-03-30 EP EP10711685A patent/EP2413928A1/en not_active Withdrawn
- 2010-03-30 SG SG2011070745A patent/SG174609A1/en unknown
- 2010-03-30 AU AU2010230211A patent/AU2010230211A1/en not_active Abandoned
- 2010-03-30 US US13/260,961 patent/US8685935B2/en not_active Expired - Fee Related
- 2010-03-30 WO PCT/EP2010/054215 patent/WO2010112510A1/en active Application Filing
- 2010-03-30 MX MX2011010376A patent/MX2011010376A/es not_active Application Discontinuation
- 2010-03-30 CN CN2010800226972A patent/CN102448455A/zh active Pending
- 2010-03-31 AR ARP100101092A patent/AR076040A1/es unknown
-
2011
- 2011-09-30 CL CL2011002451A patent/CL2011002451A1/es unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003073279A (ja) * | 2001-08-31 | 2003-03-12 | Toyo Seito Kk | 即効性および持続性を有するフラボノイド配糖体を含有する経口栄養補給剤 |
US20030144219A1 (en) * | 2001-11-15 | 2003-07-31 | Phinney Stephen Dodge | Formulations and methods for treatment or amelioration of inflammatory conditions |
JP2009209066A (ja) * | 2008-03-03 | 2009-09-17 | Toyo Seito Kk | 生体吸収性に優れたヘスペレチン組成物 |
Non-Patent Citations (1)
Title |
---|
JPN6015008869; Pharmaceutical Research Vol.21, No.7 (2004), 1263-1273 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016216440A (ja) * | 2015-05-14 | 2016-12-22 | 花王株式会社 | カテキン類吸収促進剤 |
JP2019515022A (ja) * | 2016-05-16 | 2019-06-06 | グローバル バイオライフ インコーポレーテッドGlobal Biolife Inc. | 炎症関連疾患及び障害を治療するための求電子的に強化されたフェノール化合物 |
JP2022058792A (ja) * | 2016-05-16 | 2022-04-12 | グローバル バイオライフ インコーポレーテッド | 炎症関連疾患及び障害を治療するための求電子的に強化されたフェノール化合物 |
JP7376624B2 (ja) | 2016-05-16 | 2023-11-08 | グローバル バイオライフ インコーポレーテッド | 炎症関連疾患及び障害を治療するための求電子的に強化されたフェノール化合物 |
JP2019151568A (ja) * | 2018-03-01 | 2019-09-12 | アサヒ飲料株式会社 | 酸性スフィンゴミエリナーゼ活性向上剤、酸性スフィンゴミエリナーゼ活性向上用組成物、及び抗アレルギー用組成物 |
WO2020153710A3 (ko) * | 2019-01-22 | 2020-10-15 | 조선대학교 산학협력단 | 헤스페레틴을 포함하는 피부과민반응을 조절하기 위한 조성물 |
KR20230095911A (ko) * | 2021-11-16 | 2023-06-29 | 가부시키가이샤 다이토 기켄 | 커피머신 |
KR102566640B1 (ko) | 2021-11-16 | 2023-08-11 | 가부시키가이샤 다이토 기켄 | 커피머신 |
Also Published As
Publication number | Publication date |
---|---|
WO2010112510A1 (en) | 2010-10-07 |
EP2413928A1 (en) | 2012-02-08 |
CL2011002451A1 (es) | 2012-04-20 |
SG174609A1 (en) | 2011-10-28 |
CN102448455A (zh) | 2012-05-09 |
AR076040A1 (es) | 2011-05-11 |
MX2011010376A (es) | 2011-10-12 |
BRPI1014083A2 (pt) | 2016-04-19 |
US20120022010A1 (en) | 2012-01-26 |
US8685935B2 (en) | 2014-04-01 |
AU2010230211A1 (en) | 2011-11-03 |
EP2241313A1 (en) | 2010-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8685935B2 (en) | Use of flavonoids to increase the bioavailability of hesperetin | |
Mani et al. | Chrysin: Sources, beneficial pharmacological activities, and molecular mechanism of action | |
Mitra et al. | Prospective multifunctional roles and pharmacological potential of dietary flavonoid narirutin | |
US10842805B2 (en) | Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses | |
CA2999763C (en) | Flavonoid compositions and methods of use | |
Mollace et al. | Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies | |
Lee et al. | Pharmacokinetics of quercetin absorption from apples and onions in healthy humans | |
KR102459500B1 (ko) | 퀘르세틴 배당체를 함유하는 근위축 억제제 | |
EP2040708B1 (en) | Quercetin-containing compositions | |
ES2863561T3 (es) | Fitocomplejos de Citrus bergamia | |
Salehi et al. | Hesperetin’s health potential: Moving from preclinical to clinical evidence and bioavailability issues, to upcoming strategies to overcome current limitations | |
Pandey et al. | Andrographolide: its pharmacology, natural bioavailability and current approaches to increase its content in Andrographis paniculata | |
AU2018203677A1 (en) | Modified polyphenol compositions | |
Fernández‐Fernández et al. | Citrus waste recovery for sustainable nutrition and health | |
EP2859896B1 (en) | Pharmaceutical compositions for the treatment of muscular disorders | |
F Nabavi et al. | Natural compounds used as therapies targeting to amyotrophic lateral sclerosis | |
González-Gallego et al. | Anti-inflammatory, immunomodulatory, and prebiotic properties of dietary flavonoids | |
JPWO2006135084A1 (ja) | 脂肪性肝炎または脂肪肝の予防または治療薬 | |
Pashaei | Features of apigenin, luteolin, hesperetin and naringenin in crop and body | |
KR20170023910A (ko) | 퀘르세틴-3-o-글루코시드를 포함하는 비알콜성 지방간 예방 또는 치료용 약학적 조성물 | |
KR101171832B1 (ko) | 부작용을 제거한 장기간 복용 차 및 그 조성물 | |
RU2408383C1 (ru) | Композиция с противоопухолевой и адаптогенной активностью (варианты) и лекарственный препарат на ее основе (варианты) | |
CN102205010A (zh) | 一种具有辅助降血脂功能的药物组合物 | |
AU2015221487A1 (en) | Use of flavonoids to increase the bioavailability of hesperetin | |
Cannataro et al. | Polyphenols in the Mediterranean Diet: From Dietary Sources to microRNA Modulation. Antioxidants 2021, 10, 328 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130318 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130318 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140430 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140708 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150310 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150610 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150811 |